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Summary 
Two recent reports convincingly demonstrate that the risk of schizophrenia is influenced by common 
variation of C4, which codes for complement component 4, and by rare, disruptive mutations of 
SETD1A, which codes for a histone methylase. These important results open the way for major 
advances in our understanding of the fundamental biological processes leading to disease. 
Text 
Recent weeks have seen dramatic advances in schizophrenia genetics research, with the first 
definitive identification of specific coding variations directly affecting schizophrenia risk. Two 
separate genes have been implicated: common variation in C4, which codes for complement 
component 4, exerts a modest effect on schizophrenia risk which, in the large samples studied, was 
statistically significant at p=3.5x10-24(1); by contrast, very rare variants disrupting SETD1A, which 
codes for a component of a histone methyl transferase, exert a very large effect on risk which was 
significant at p=3.3x10-9(2). The importance of these findings does not relate to their immediate 
clinical implications. At an individual level, C4 variation has a negligible effect on risk and only a very 
small fraction of patients will possess SETD1A variants. Rather, these findings for the first time give 
us a concrete opening into understanding the biology of schizophrenia. 
Previous findings in schizophrenia genetics could be broadly grouped into three main classes: 
individual variants which were of questionable statistical significance and which await replication; 
genetic markers which showed statistically robust association but which were not themselves 
causative and which did not implicate any individual gene (3); rare chromosomal deletions and 
duplications which definitely exerted a large effect on risk but which each contained multiple genes, 
meaning that one could not determine which were of relevance (4). Arguably, the single exception 
to this would be that some pathogenic chromosome 2 deletions are so small as to only affect a single 
gene, NRXN1. Another exception could be made for DISC1, in that the originally reported 
translocation does definitely increase the risk of schizophrenia and other mental disorders (5). 
However no other disease-causing variants in DISC1 have been conclusively identified, despite 
extensive attempts. Thus the latest findings are widely perceived as marking a real step forward and 
as taking us into new territory. 
The study of C4 was driven by the finding that many markers in the HLA region, where it is located, 
demonstrate significant association with schizophrenia (1). Intensive studies of the gene revealed 
that it could vary in any of three different ways: firstly, the number of copies of the gene on each 
chromosome can vary; secondly, each copy can be "long" or "short", depending on whether or not it 
harbours a small insertion of viral origin; thirdly, a variation in DNA sequence means that each copy 
can be denoted as either "C4A" or "C4B", with these two forms of the gene producing versions of the 
protein product having different properties. The specific C4 gene or genes found on a chromosome 
can be referred to as a haplotype and the study showed that four different haplotypes commonly 
occur. The level of C4A expression produced by each haplotype varies and the predicted C4A 
expression correlated with schizophrenia risk at p=3.5x10-24. The highest risk haplotype, consisting of 
two long forms of C4A, confers increased risk by a factor of 1.27 over the lowest risk haplotype, 
consisting of a single copy of the short form of C4B. The study also demonstrated that complement 
component 4 is found on neurons and synapses, so it would be legitimate to speculate that 
increased C4A expression could lead to increased synaptic pruning. Indeed, the authors were able to 
demonstrate that mice manipulated to lack C4 had reduced synaptic pruning. 
The SETD1A study represented an extension and confirmation of previous research which had 
demonstrated that schizophrenic subjects with unaffected parents could possess de novo variants, 
i.e. not found in either parent,  which disrupted SETD1A (6). The recent study demonstrated this was 
a more widespread phenomenon, confirming its validity (2). Loss of function (LOF) variants were 
defined as those which would seriously disrupt correct translation of the gene, either through 
introducing a premature stop codon, shifting the reading frame or preventing normal splicing. Such 
LOF variants were found in a total of 10 out of nearly 8,000 schizophrenic subjects but none of over 
13,000 thousand controls. This implies that if one has only one working copy of this gene, rather 
than two, then the risk of developing schizophrenia is very substantially increased. LOF variants in 
SETD1A were also identified in 4 out of 3,148 children with diverse, severe, developmental disorders, 
suggesting that this can be an alternative outcome. SETD1A is involved in the methylation of a lysine 
residue in histone tails, a process which leads to increased expression of other genes. In particular, 
there are suggestions that this may affect genes involved in synaptic function and GABAergic 
signaling, as well as dopaminergic and glutamatergic transmission (7). It is of note that mutations in 
genes with similar to SETD1A are known to cause developmental disorders such as Wiedemann-
Steiner syndrome, Kleefstra syndrome and Kabuki syndrome. Likewise, there is independent 
evidence that other genes involved in histone modification also influence risk of schizophrenia (8) 
(9). 
Thus these two findings appear to implicate two very different biological pathways affecting 
schizophrenia risk. The former demonstrates a role for complement, perhaps specifically that 
increased C4A expression leads to increased synaptic pruning. Although the effect of naturally 
occurring variation is small, this does not mean that pharmacological targeting of this process might 
not exert substantial effects on the development and/or course of schizophrenia. The latter finding 
implicates broad effects on gene expression which seem to result in a surprisingly narrow 
phenotypic effect. Because of the magnitude of this effect, one could argue that testing for SETD1A 
variants should become part of the routine management of schizophrenia, alongside testing for 
pathogenic copy number variants (4). 
The implications of these findings are so far-reaching that it is impossible to do them justice in the 
space available. Both will followed by molecular studies which will seek to gain further insight into 
the mechanisms by which these variants affect risk and this process is likely to lead to the 
implication of additional related genes. Thus, although the contribution which the currently 
identified variants make towards the overall risk of schizophrenia in the population is small, the 
concrete nature of these findings means that it is reasonable to expect that they will progress 
towards a situation in which we attain a far more substantial understanding of the molecular 
mechanisms involved in schizophrenia aetiology. Many workers in psychiatric genetics feel that the 
field has entered a long-awaited new phase and look forward with enthusiasm to further 
developments. 
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